Your browser is no longer supported. Please, upgrade your browser.
Settings
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
INO [NASD]
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own2.00% Shs Outstand98.53M Perf Week24.71%
Market Cap417.77M Forward P/E- EPS next Y-0.80 Insider Trans0.54% Shs Float96.23M Perf Month13.98%
Income-114.70M PEG- EPS next Q-0.24 Inst Own41.80% Short Float10.82% Perf Quarter82.76%
Sales6.30M P/S66.31 EPS this Y2.90% Inst Trans-0.12% Short Ratio7.86 Perf Half Y58.21%
Book/sh0.34 P/B12.47 EPS next Y25.90% ROA-71.80% Target Price9.43 Perf Year-15.37%
Cash/sh0.95 P/C4.45 EPS next 5Y0.00% ROE-181.90% 52W Range1.91 - 5.11 Perf YTD28.48%
Dividend- P/FCF- EPS past 5Y6.10% ROI-110.80% 52W High-17.03% Beta2.22
Dividend %- Quick Ratio5.10 Sales past 5Y17.70% Gross Margin- 52W Low121.41% ATR0.32
Employees281 Current Ratio5.10 Sales Q/Q-55.00% Oper. Margin- RSI (14)74.10 Volatility10.34% 7.36%
OptionableYes Debt/Eq2.08 EPS Q/Q13.80% Profit Margin- Rel Volume18.39 Prev Close3.84
ShortableYes LT Debt/Eq2.08 EarningsFeb 11 AMC Payout- Avg Volume1.33M Price4.24
Recom1.90 SMA2027.35% SMA5046.85% SMA20052.13% Volume24,372,813 Change10.42%
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Sep-09-15Reiterated Maxim Group Buy $20 → $23
Mar-12-15Initiated H.C. Wainwright Buy $17
Jul-24-14Upgrade Aegis Capital Hold → Buy $10 → $19
May-07-14Initiated Stifel Buy $4
Mar-18-14Reiterated Maxim Group Buy $3 → $6
Jan-24-14Reiterated Brean Capital Buy $3 → $4
Aug-16-13Downgrade Aegis Capital Buy → Hold
Jul-09-13Reiterated Maxim Group Buy $1 → $2
Jan-25-20 10:58AM  Second coronavirus patient identified, extent and duration of airport screening to be re-evaluated MarketWatch
Jan-24-20 09:20AM  Coronavirus-Linked Stock Speculation Reminds Health Sector of Bitcoin Bloomberg +10.42%
08:59AM  Coronavirus Spooks Global Markets: Winners and Losers Zacks
08:55AM  CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs Zacks
07:24AM  Inovios stock soars after receiving grant to develop coronavirus vaccine MarketWatch
Jan-23-20 01:43PM  Montco biopharm firm gets $9M grant to battle China's new coronavirus American City Business Journals +11.63%
01:02PM  13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak Benzinga
11:26AM  Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus PR Newswire
11:01AM  UPDATE: Vaccine stocks rise sharply as coronavirus fears mounts MarketWatch
09:15AM  Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus PR Newswire
Jan-22-20 02:28PM  Health stocks reverse coronavirus gains as one analyst says the market is overreacting Yahoo Finance
08:54AM  Implied Volatility Surging for Inovio (INO) Stock Options Zacks
Jan-21-20 02:40PM  Experimental vaccine stocks jump on concerns about new virus in China MarketWatch +8.21%
Jan-15-20 08:00AM  Inovio Welcomes Biotech Leader to its Board of Directors PR Newswire
Jan-06-20 08:00AM  Inovio Provides Update on Clinical Program Plans for 2020 PR Newswire +5.37%
Jan-03-20 03:09PM  Edited Transcript of INO earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -7.17%
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-20-19 10:04AM  Merck's Ebola Vaccine Ervebo Gets Approval in United States Zacks
Dec-12-19 11:30AM  Inovio (INO) Up 14.3% Since Last Earnings Report: Can It Continue? Zacks
Nov-29-19 11:10AM  Hedge Funds Cashed Out Of Inovio Pharmaceuticals Inc (INO) Too Early Insider Monkey
Nov-25-19 09:00AM  Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference PR Newswire
Nov-15-19 09:00AM  Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference PR Newswire +6.82%
Nov-13-19 10:03AM  Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus Zacks -5.33%
Nov-12-19 06:05PM  Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM  Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results PR Newswire
08:05AM  Merck's Ebola Vaccine Gets Conditional Approval in Europe Zacks
Nov-05-19 10:32AM  Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +6.30%
08:00AM  Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) PR Newswire
Nov-04-19 04:30AM  INO: Great Things Take Time, And Nows the Time Zacks Small Cap Research
Nov-01-19 10:02AM  Investors Who Bought Inovio Pharmaceuticals (NASDAQ:INO) Shares Five Years Ago Are Now Down 81% Simply Wall St. +7.04%
Oct-29-19 09:25AM  Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019 PR Newswire -5.17%
Oct-10-19 08:42AM  QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits Zacks
Sep-25-19 02:49AM  Edited Transcript of INO earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-17-19 09:00AM  Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection PR Newswire -6.69%
Sep-07-19 09:30AM  Inovio (INO) Down 16.1% Since Last Earnings Report: Can It Rebound? Zacks
Sep-03-19 09:00AM  Inovio Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Aug-26-19 04:49PM  Inovio (INO) Down More Than 30% in 3 Months: Here's Why Zacks
Aug-20-19 05:14PM  Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100 Zacks
Aug-19-19 09:00AM  Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia PR Newswire
Aug-09-19 01:23PM  Inovio Pharmaceuticals, Inc. (INO) Q2 2019 Earnings Call Transcript Motley Fool
11:16AM  Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates Zacks
Aug-08-19 06:05PM  Inovio Pharmaceuticals (INO) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:05PM  Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results PR Newswire
Aug-07-19 10:19AM  Montco biotech could become first U.S. company listed on Nasdaq, Korean exchanges American City Business Journals
Aug-06-19 04:05PM  Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea PR Newswire -5.88%
Aug-01-19 10:33AM  Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline Zacks
Jul-30-19 10:38AM  Earnings Preview: Inovio Pharmaceuticals (INO) Q2 Earnings Expected to Decline Zacks
09:00AM  Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019 PR Newswire
Jul-25-19 09:00AM  Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases PR Newswire
Jul-17-19 11:20AM  Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs Zacks -9.67%
09:16AM  Why Inovio Pharmaceuticals Stock Is Plunging Today Motley Fool
Jul-16-19 08:08PM  Inovio narrows focus, eliminates 80 jobs American City Business Journals
04:05PM  Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates PR Newswire
11:08AM  Should You Worry About Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) CEO Salary Level? Simply Wall St.
Jul-10-19 08:00AM  Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology PR Newswire
Jul-09-19 09:54AM  Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 Zacks
Jul-08-19 09:00AM  Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN) PR Newswire
Jun-27-19 10:18AM  Inovio Up on Enrollment Closure in Cervical Dysplasia Study Zacks
Jun-26-19 09:47AM  Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer PR Newswire +19.84%
Jun-25-19 09:28AM  Inovio Inks $35M Chinese Drug License Deal (INO) Investopedia
Jun-10-19 03:55PM  Inovio Pharmaceuticals, Inc. (NASDAQ:INO): Time For A Financial Health Check Simply Wall St.
09:00AM  Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device PR Newswire
Jun-08-19 09:31AM  Inovio (INO) Down 36.7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-06-19 11:54AM  State picks next president of Georgia Tech American City Business Journals
Jun-04-19 11:15AM  Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sold $5 million of Shares GuruFocus.com +5.49%
May-31-19 11:25AM  Why Inovio Pharmaceuticals Stock Is Sinking Today Motley Fool -14.95%
May-29-19 07:38AM  The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation Benzinga
May-28-19 08:38PM  After Hours: DowDuPont Spinoff Leaping to the S&P 500, Inovio's Partner Problems Motley Fool
06:19PM  Inovio Pharma stock slips as AstraZeneca unit scales back agreement MarketWatch
05:27PM  Stocks making the biggest moves after hours: Workday, Inovio and more CNBC
May-21-19 09:00AM  Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial PR Newswire
May-17-19 11:53AM  QIAGEN Partners Inovio to Develop Companion Diagnostics Zacks
08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
May-16-19 04:02PM  Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer PR Newswire
May-15-19 09:00AM  Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus PR Newswire
May-10-19 10:21AM  Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates Zacks
06:00AM  What You'll Want to Know About Inovio Pharmaceuticals' Q1 Earnings Update Motley Fool
03:49AM  Edited Transcript of INO earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
02:23AM  Inovio Pharmaceuticals Inc (INO) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 06:25PM  Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:19PM  Inovio: 1Q Earnings Snapshot Associated Press
04:05PM  Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results PR Newswire
02:48PM  If You Had Bought Inovio Pharmaceuticals (NASDAQ:INO) Stock Three Years Ago, You'd Be Sitting On A 58% Loss, Today Simply Wall St.
May-07-19 04:48PM  What's in the Cards for AcelRx (ACRX) This Earnings Season? Zacks -6.08%
07:53AM  What's in Cards for Cumberland (CPIX) This Earnings Season? Zacks
May-06-19 09:38AM  What's in the Cards for Corbus (CRBP) This Earnings Season? Zacks
09:00AM  Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100 PR Newswire
May-02-19 04:39PM  Protalix (PLX) to Report Q1 Earnings: What's in the Cards? Zacks
May-01-19 10:32AM  Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? Zacks
09:00AM  Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019 PR Newswire
Apr-18-19 02:43PM  Cover story: Joseph Kim's art of the bio-deal American City Business Journals
09:00AM  Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs) in a Peer-reviewed Journal PR Newswire
06:00AM  Inovio- A Biotech Bet for New World Investors MoneyShow
Apr-17-19 09:00AM  Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress PR Newswire -5.34%
Apr-11-19 09:30AM  Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue? Zacks
Apr-09-19 11:37AM  One Thing To Remember About The Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Share Price Simply Wall St.
10:30AM  Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457 Zacks
Apr-08-19 09:00AM  Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development PR Newswire
Apr-04-19 10:36AM  Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks
Apr-03-19 09:00AM  Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study PR Newswire
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kim Jong JosephChief Executive OfficerJan 13Buy3.1122,50069,9751,100,707Jan 13 12:10 PM
Humeau LaurentChief Scientific OfficerAug 30Buy2.224,5009,99050,333Sep 04 09:57 AM
Weiner David B.DirectorAug 01Sale2.7216,35244,477797,110Aug 02 05:00 PM
Humeau LaurentChief Scientific OfficerJun 05Buy2.5020,00050,00045,833Jun 05 05:19 PM
Kim Jong JosephChief Executive OfficerJun 03Sale2.31296,705684,736816,527Jun 04 09:00 AM
Kim Jong JosephChief Executive OfficerJun 03Sale2.30832,8481,914,4681,078,207Jun 04 09:00 AM
Kim Jong JosephChief Executive OfficerMay 31Sale2.40500,0001,200,8001,113,232Jun 04 09:00 AM
Kim Jong JosephChief Executive OfficerMay 31Sale2.44500,0001,217,6501,911,055Jun 04 09:00 AM
Kim Jong JosephChief Executive OfficerMay 21Sale3.31100,000331,0002,411,055May 23 04:21 PM
Kim Jong JosephChief Executive OfficerMay 16Sale3.5061,212214,2421,613,232May 17 04:44 PM
Kim Jong JosephChief Executive OfficerMay 15Sale3.5075,556264,4461,674,444May 17 04:44 PM